- Oral presentation will feature HS135, the Company’s Phase 1 novel Activin and GDF inhibitor
Montreal, QC, Canada (Mar 25, 2024) – 35Pharma, a clinical-stage biopharmaceutical company that designs and develops TGF-beta superfamily therapeutics, today announced that it has been selected for an oral presentation at the American College of Cardiology 73rd Annual Scientific Session (ACC.24) in Atlanta, GA, USA (April 6 – 8, 2024).
The presentation will feature pre-clinical data on HS135, the Company’s Phase 1 novel Activin and GDF inhibitor, in models of Pulmonary Hypertension and Heart Failure as part of Session 904, “Highlighted Original Research: Pulmonary Vascular Disease and the Year in Review”.
Details of the presentation are as follows:
- Date: April 7th, 2024
- Time of presentation: 9:02 AM – 9:12 AM
- Location: Georgia World Congress Center, Atlanta, GA, Room B314
About 35Pharma
35Pharma is a clinical-stage biopharmaceutical company specializing in TGF-beta superfamily therapeutics for the treatment of Pulmonary Hypertension, Heart Failure and obesity. 35Pharma leverages its scientific leadership in TGF-beta biology combined with superior protein engineering to discover innovative compounds that selectively and potently neutralize validated pathological TGF-beta ligands while sparing beneficial homeostatic ligands.
Contact
Julia Schoelermann, VP Corporate Development, 35Pharma
info@35pharma.com
For more information, please visit www.35pharma.com
